sed
routinely for evaluation of melanocytic lesions. Imaging a single lesion
using the VivaScope(R) required just 5 to 10 minutes according to the
authors," continued Eastman, "which makes it practical for everyday use in
private dermatology practices worldwide."
Study Detailed in the Journal of Investigative Dermatology
The entire paper recounting the study can be found in the Journal of
Investigative Dermatology (2007), 0, 000-000, doi: 10.1038/sj.jid.5700993,
"The Impact of In Vivo Reflectance Confocal Microscopy for the Diagnostic
Accuracy of Melanoma and Equivocal Melanocytic Lesions," authors Giovanni
Pellacani, Pascale Guitera, Caterina Longo, Michelle Avramidis, Stefania
Seidenari and Scott Menzies. On the Web, visit
http://dx.doi.org/10.1038/sj.jid.5700993 .
Authors Pellacani, Longo, and Seidenari are of the Department of
Dermatology, University of Modena and Reggio Emilia, Modena, Italy.
Guitera, Avramidis, and Menzies are of the Faculty of Medicine, Sydney
Melanoma Diagnostic Centre, Sydney Cancer Centre and Dermatology
Department, Royal Prince Alfred Hospital, University of Sydney, Sydney,
Australia.
This paper builds on the results of an earlier pilot study that was
published in the December 2005 issue of the Journal of the American Academy
of Dermatology, beginning on page 979 of that issue.
About Lucid Inc.
Lucid Inc., based in Rochester, New York, USA, is a medical device and
information company dedicated to creating innovative cellular imaging
technology and using the Internet to securely deliver accurate, real-time
VivaScope(R) cellular resolution images to medical professionals. When
coupled with its digital VivaNet(TM) system, the company's ability to image
in-vivo (living) tissue will aid medical practitioners and pathologists in
skin cancer screening with clarity, speed and patient comfort. For more
information about Lucid Inc., visit '/>"/>
SOURCE Lucid Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
Urinalysis Analyzers: Large Capabilities in Every Size Device2.
Large Geographic Differences in EpiPen Prescriptions in the U.S.,
From the Journal of Allergy and Clinical Immunology3.
Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society4.
Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types5.
Largest National U.S. Healthcare Facility MRSA Study Reveals
Infection Rates Eight Times Greater Than Previous Estimates6.
Newly Published Data from Large Study Support Cardiovascular Safety
of Avandia (Rosiglitazone Maleate)7.
MedImmune Announces Positive Clinical Results at PAS Annual Meeting
From Large Prospective Trial in Prevention of Serious RSV Disease8.
First Controlled Large-Scale Intervention Angiotensin Receptor
Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study
Demonstrates Significant Reduction in Blood Pressure and Protection
of Organs with Valsartan9.
Large Study Shows that Presence of Neutralizing Antibodies Did Not
Predict Clinical Response to Betaseron Treatment10.
Medical Journal Publishes First Large-Scale Survey Revealing
Experiences of IPF Patients11.
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma